Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 11Oxaliplatin 6Fluorouracil 6Capecitabine 5pembrolizumab 4Paclitaxel 4Leucovorin 4durvalumab 3Radiotherapy 3Folfox protocol 3Drug Therapy 3dehydroftorafur 2Trastuzumab 2Specimen Handling 2Radiation 2Metformin 2Magnetic Resonance Spectroscopy 2Itraconazole 2Irinotecan 2Docetaxel 2Cisplatin 2Carboplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma Of Esophagus × Rosiglitazone × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡